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INTRODUCTION
Obstructive sleep apnea (OSA) is a condition character-
ized by repeated upper airway obstruction during sleep, recur-
rent oxygen desaturations, and increased arousals from sleep. 
Untreated OSA is associated with an increased risk of hyper-
tension,1 motor vehicle crashes,2 and neurocognitive impair-
ment,3 and increasing evidence has come to light to support a 
possible causal link between OSA and cardiovascular disease 
(CVD).4-6 Continuous positive airway pressure (CPAP) therapy 
has been shown to improve symptoms of excessive sleepiness 
and quality of life, and reduce the risk of motor vehicle crashes 
in patients with OSA,7,8 and is considered the primary form of 
therapy for symptomatic, moderate to severe disease.
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Study Objectives: To determine the clinical variables that best predict long- term continuous positive airway pressure (CPAP) adherence among 
patients with cardiovascular disease who have obstructive sleep apnea (OSA).
Design: 12-mo prospective within-trial observational study.
Setting: Centers in China, Australia, and New Zealand participating in the Sleep Apnea cardioVascular Endpoints (SAVE) study.
Patients: There were 275 patients age 45-70 y with cardiovascular disease (i.e., previously documented transient ischemic attack, stroke, or 
coronary artery disease) and OSA (4% oxygen desaturation index (ODI) > 12) who were randomized into the CPAP arm of the SAVE trial prior to 
July 1, 2010.
Methods: Age, sex, country of residence, type of cardiovascular disease, baseline ODI, severity of sleepiness, and Hospital Anxiety and Depression 
Scale (HADS) scores plus CPAP side effects and adherence at 1 mo were entered in univariate analyses in an attempt to identify factors predictive 
of CPAP adherence at 12 mo. Variables with P < 0.2 were then included in a multivariate analysis using a linear mixed model with sites as a random 
effect and 12-mo CPAP use as the dependent outcome variable.
Measurements and Results: CPAP adherence at 1, 6, and 12 mo was (mean ± standard deviation) 4.4 ± 2.0, 3.8 ± 2.3, and 3.3 ± 2.4 h/night, 
respectively. CPAP use at 1 mo (effect estimate ± standard error, 0.65 ± 0.07 per h increase, P < 0.001) and side effects at 1 mo (-0.24 ± 0.092 per 
additional side effect, P = 0.009) were the only independent predictors of 12- mo CPAP adherence.
Conclusion: Continuous positive airway pressure use in patients with coexisting cardiovascular disease and moderate to severe obstructive sleep 
apnea decreases significantly over 12 months. This decline can be predicted by early patient experiences with continuous positive airway pressure 
(i.e., adherence and side effects at 1 month), raising the possibility that intensive early interventions could improve long-term continuous positive 
airway pressure compliance in this patient population.
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The Sleep Apnea cardioVascular Endpoints (SAVE) study 
(NCT00738179, ClinicalTrials.gov) is a large, international, 
multicenter, randomized controlled trial that aims to deter-
mine whether the addition of CPAP to standard medical 
treatment will reduce cardiovascular (CV) events in patients 
with coexisting CVD and moderate to severe OSA9. In this 
study, patients with a history of coronary artery disease or 
cerebrovascular disease have been randomized to receive 
either CPAP and standard care, or standard care alone, for 
an average 4-y follow-up. Patient adherence to CPAP in the 
treatment arm will be critically important for the success of 
this long-term study.
Although highly effective in abolishing sleep disordered 
breathing events and minimizing symptoms of OSA, CPAP 
therapy is not always well tolerated by patients and long-term 
adherence to treatment can be problematic. Previous studies 
examining CPAP adherence in patients with OSA have reported 
that the rates of CPAP nonadherence, as defined by a mean use 
of < 4 h per night, can vary from anywhere between 29% to 
83%.10 Increased hours of CPAP use per night has been shown 
to be associated with greater improvements in OSA symptoms, 
daytime sleepiness, quality of life, and blood pressure.11-13
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It has been proposed that long-term patterns of CPAP adher-
ence are established as early as the first week after commence-
ment of therapy.14,15 However, no individual factor has been 
shown to consistently predict CPAP use, and adherence to 
therapy is thought to be influenced by a complex array of, as yet, 
poorly characterized factors that may vary among individuals.16 
Patient characteristics such as age, sex, and marital status have 
not consistently been shown to be predictors of CPAP adher-
ence. Severity of OSA, as determined by the apnea-hypopnea 
index (AHI), oxygen desaturation index (ODI), or daytime 
sleepiness, have been shown to have a weak relationship with 
CPAP use in some studies,17-19 but this has not been consistently 
demonstrated.15 CPAP side effects also have not been consis-
tently shown to influence CPAP adherence.20-22
Previous studies of long-term CPAP adherence have 
predominantly involved patients in whom symptomatic OSA 
has been diagnosed in a sleep clinic. In contrast, the SAVE 
study has focused on patients with OSA and CVD who have 
been recruited predominantly from cardiology and neurology 
clinics and who might therefore be expected to be less symp-
tomatic than sleep clinic patients. Furthermore, the SAVE study 
protocol dictates that subjects with very high levels of daytime 
sleepiness (i.e., Epworth Sleepiness Scale (ESS) score > 15) 
be excluded. Greater levels of subjective daytime sleepiness as 
measured by ESS, as well as a patient’s perception of symptom-
atic benefit , have previously been observed to predict CPAP 
use.17,20,23,24 Thus, CPAP compliance could potentially be prob-
lematic in patients, such as those in the SAVE study, who report 
few OSA symptoms prior to commencement of therapy. Alter-
natively, because patients with OSA and CVD might believe 
that they could potentially benefit from CPAP, patients recruited 
into the SAVE study may be more motivated to comply with 
treatment, resulting in high levels of compliance.
Recruitment for the SAVE study commenced initially in 
China, and then in Australia and New Zealand. Although 
African-American race has been shown to be associated with 
increased risk of nonadherence compared with Caucasian 
patients, few studies have compared the patterns of CPAP use 
among other ethnic groups, including the Chinese population. 
One study examining the predictors of CPAP use in a group of 
Chinese patients with OSA revealed a high baseline AHI as the 
only independent predictor of increased CPAP compliance at 
1 and 3 mo.21
The aims of this study were to evaluate the average nightly 
hours of CPAP use in the first 12 mo for patients randomized 
into the treatment arm of the SAVE study, and to identify the 




All patients randomized into the CPAP treatment arm of 
the SAVE study from the commencement of recruitment on 
December 28, 2008 and prior to July 1, 2010, who survived 
for at least 12 mo postrandomization and for whom we had at 
least 1 and 12 mo of CPAP adherence data, were included in the 
analysis. Participants in the SAVE study were age 45-75 y and 
had established CVD and coexisting moderate to severe OSA. 
Participants in the current study were recruited from 37 centers 
in China, nine in Australia, and four in New Zealand. Estab-
lished CVD was defined as a history of coronary artery disease 
(i.e., previous myocardial infarction ≥ 90 days prior; stable 
or unstable angina with a diagnostic coronary angiography or 
positive exercise stress test; multivessel percutaneous angio-
plasty and/or stent ≥ 90 days prior; and/or multivessel coronary 
artery bypass graft ≥ 1 y prior) or a history of cerebrovascular 
disease (i.e., previous stroke ≥ 90 days prior or neurologist-
diagnosed transient ischemic attack (TIA) of the brain or retina 
30 days to 1 y prior). Patients were excluded from participation 
if they had any of the following: coronary or carotid revascular-
ization procedure planned within the next 6 mo; severe respira-
tory disease, defined as severe chronic obstructive pulmonary 
disease (forced expiratory volume in 1 s (FEV1)/forced vital 
capacity < 70% and FEV1 < 50%) or resting awake oxygen 
saturation (SaO2) ≤ 90% by ApneaLinkTM (ResMed, Sydney, 
Australia); New York Heart Association heart failure categories 
III-IV; stroke due to subarachnoid haemorrhage; other house-
hold member enrolled in the study; prior use of CPAP for OSA; 
increased risk of a sleep related motor vehicle accident and/
or excessive daytime sleepiness (driver occupation; fall asleep 
or near-miss accident in the previous 12 mo; and/or an ESS 
score > 15); > 10% overnight recording time with SaO2 ≤ 80%; or 
Cheyne-Stokes respirations identified during ApneaLink moni-
toring. A diagnosis of moderate to severe OSA was determined 
using a ≥ 4% oxygen desaturation index (≥ 4% ODI) ≥ 12/h 
on overnight monitoring with an ApneaLink device, which has 
been shown to have a high diagnostic accuracy for moderate 
to severe OSA (i.e., American Academy of Sleep Medicine 
1999 criteria25 AHI ≥ 30/h)26. The SAVE study was approved 
by the relevant human research and ethics committees for each 
participating site and all participants provided written informed 
consent.
CPAP Initiation
Prior to study entry, potentially eligible participants under-
took a 1-w run-in period with sham CPAP in order to exclude 
patients who were unable to comply with CPAP therapy (i.e. 
average use < 3 h/night). Patients who successfully completed 
the sham run-in phase were then randomized to receive either 
CPAP treatment in addition to standard care, or standard care 
alone, using a web-based randomisation program with stratifi-
cation of treatment allocation by site, type of CVD, and OSA 
severity (i.e., ESS). For patients assigned to the CPAP treatment 
group, autotitrating CPAP (REMstar Auto M Series, Philips 
Respironics Inc, USA) was commenced for a 1-w period to 
determine a fixed treatment pressure (based on the 90th percen-
tile pressure as determined by the autotitrating device) for 
subsequent CPAP therapy during the study. The same CPAP 
device used during the auto-CPAP trial was used for long-term 
treatment but was converted to a fixed pressure mode. Partici-
pants were provided with on-site training on the use of CPAP, 
which included viewing of a patient education DVD and a 
phone call 3 days after starting the sham CPAP trial. Partici-
pants randomized to CPAP were reassessed for mask fit, and 
provided with take-home written materials as well as central 
review of CPAP data by sleep research staff for troubleshooting 
when needed. Sleep research staff were advised to consult the 
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“CPAP Troubleshooting Guide for SAVE Investigators/Study 
Coordinators” (Figure S1), which was contained within the 
Local Clinical Centre Manual of Procedures provided to all 
study sites to deal with complaints of CPAP side effects. Heated 
humidification was recommended if patients complained of 
nasal congestion or mouth/airway dryness, and added to CPAP 
therapy if required at the discretion of the sleep research staff. 
Remote monitoring of overall CPAP adherence at each study 
site was regularly performed each month by Regional Coor-
dinating Centres and the Core Laboratory located in Adelaide, 
Australia, to identify study sites with low average CPAP adher-
ence (i.e. < 3 h/night) or a significant proportion of patients 
with low adherence or who had discontinued CPAP therapy.
Outcome Measures
At baseline, individual demographic and anthropometric 
data were collected including patient age, sex, type of CVD, 
and body mass index (BMI). Severity of OSA was determined 
using the ≥ 4% ODI on ApneaLink monitoring, and patients 
completed an ESS score and answered questions about the 
frequency and loudness of snoring and frequency of witnessed 
apneas. Patients also completed the Hospital Anxiety and 
Depression Scale (HADS) and Short Form-36 Health Survey 
(SF-36).
Participants in the CPAP arm of the SAVE study at all study 
sites were reviewed by direct, in-person consultations with 
research staff on the day of randomization (baseline, day 0), at 
1 w, and then at 1, 3, and 6 mo, and then every 6 mo thereafter. 
CPAP adherence (i.e., average h of use per night) was objec-
tively monitored on CPAP devices using an inbuilt compliance 
meter with breathing detection that was downloaded by research 
staff at each review appointment. The residual AHI and average 
leak scores were also recorded and downloaded from CPAP 
devices. Adverse events and/or problems associated with CPAP 
use were documented and categorized into seven main types 
(i.e., mouth dryness; nasal symptoms; eye problems; claustro-
phobia; noise problems; facial soreness or skin irritation from 
the mask; and mask fit or leak problems [i.e. trouble keeping the 
mask in place, air leaks from the mask or difficulty putting the 
mask on]), with a patient receiving a score of one point for the 
presence of any complaints within each category, producing a 
total possible side effect score of seven points.
Data Collection and Statistical Analysis
Baseline patient characteristics, including demographic data, 
BMI, type of CVD, and measures of OSA severity (i.e. ESS and 
ODI), were calculated according to the region of recruitment, 
and then for all patients combined. CPAP adherence, in terms 
of the mean h of daily use, was calculated at each review for the 
preceding period (i.e., 5 to 10 days before randomization for the 
sham CPAP trial and randomisation to first mo, mo 4 to 6 and 
mo 7-12, for 1-, 6-, and 12-mo reviews, respectively). The 
percentage of patients adherent, as defined by CPAP use ≥ 4 h/
night, was also determined at 1, 6, and 12 mo. Patients who 
withdrew from the study during the follow-up period were 
retained for the purposes of this analysis and were deemed to 
have zero CPAP adherence at the subsequent planned follow-up 
visit times. If data were missing at 6 or 12 mo (e.g., missed visit 
or a technical problem with data download) a value was imputed 
if there were data recorded at the scheduled visits either side of 
this visit. Average daily CPAP use measured at 12 mo (i.e. the 
average daily CPAP use for the 7- to 12-mo follow-up period) 
was the dependent outcome variable of interest. Statistical anal-
yses were conducted in SAS version 9.2 (SAS Institute, Cary, 
NC, USA).
To determine predictors of long-term CPAP adherence, anal-
yses were conducted using a linear mixed model with sites as 
a random effect. Potential predictors were predetermined based 
on the results of previous studies, which have shown that a 
patient’s very early experience with CPAP appears to predict 
long-term treatment adherence. We focused particular attention 
on the influence of early (i.e., 1 mo) side effects and levels of 
CPAP adherence. For the univariate analysis, potential predic-
tors were age, sex, BMI, country of recruitment, socioeconomic 
status (SES, as determined by the gross domestic product [GDP] 
of the region of recruitment), type of medical department, CVD 
type, ≥ 4% ODI, baseline ESS and OSA symptoms, change in 
ESS from baseline to 1 mo, CPAP adherence during the sham 
trial and at 1 mo, CPAP side effects at 1 mo, and baseline HADS 
and SF-36 scores. Age, sex, country of recruitment, and vari-
ables found on univariate analysis to have a P value < 0.20 were 
included in the multivariate analysis to determine the indepen-
dent predictors of 12-mo CPAP adherence. A P value < 0.05 was 
considered to be statistically significant.
RESULTS
Baseline Characteristics
A total of 710 patients completed a 1-w trial of sham CPAP, 
603 (85%) of whom used CPAP for at least 3 h per night. There 
were 590 of these patients who were eligible for and were 
randomized into the SAVE study prior to July 1, 2010, 296 of 
whom were allocated to the CPAP study arm (Figure 1). Of 
these, 275 patients (225 patients from China, and 50 patients 
from Australia or New Zealand) had available CPAP adher-
ence data at 1 and 12 mo and were included in the analysis. 
Twenty-one patients were excluded for the following reasons: 
one patient died prior to the 12-mo review; two patients were 
found to be ineligible for the study after randomization; five 
patients were removed due to a violation of study protocol at 
the site of recruitment; data were not available for one patient 
due to failure of the CPAP download card and results could 
not be imputed; 10 patients did not attend their 12-mo review 
appointment, and two patients withdrew from the study and 
1-mo CPAP data were unavailable. Patients who were excluded 
from the analysis tended to have a higher proportion of coro-
nary artery disease than transient ischemic attack (TIA) or 
stroke, higher ESS scores, reported louder snoring, had fewer 
CPAP side effects, and had lower mean nightly hours of CPAP 
use at 1, 3, and 6 mo, compared to patients analyzed.
The baseline characteristics of the patients, separated by 
country of recruitment, are shown in Table 1. Patients enrolled 
in the SAVE study were predominantly middle-aged, over-
weight, or obese males with moderate to severe OSA. Patients 
recruited in China had a lower mean (± standard deviation 
[SD]) BMI (27.6 ± 3.7 kg/m2) than those from Australia and 
New Zealand (31.9 ± 4.3 kg/m2). However, there was a higher 
percentage of patients with more severe degrees of OSA in the 
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Chinese group (43% versus 28% with a ≥ 4% ODI > 30/h). 
Despite this, patients from Australia and New Zealand reported 
higher degrees of sleepiness on the ESS score than the Chinese 
group (36% versus 23% with ESS ≥ 10). In terms of the CVD 
type, there were similar proportions of patients with coronary 
artery disease and cerebrovascular disease in the Chinese group, 
whereas almost all patients from Australia and New Zealand 
had coronary artery disease.
CPAP Adherence
The mean nightly hours of CPAP use during the sham trial and 
at 1, 6, and 12 months are shown in Table 2. Average CPAP use 
per night was similar in the Chinese and Australia/New Zealand 
groups at all time points. Over the first 12 mo of the SAVE 
trial, there appeared to be a progressive decline in mean nightly 
CPAP use in both the Chinese and Australia/New Zealand 
groups, which fell from 4.4 ± 2.0 h/night at 1-mo follow-up to 
3.3 ± 2.4 h/night at 12 mo in the two groups combined.
Table 3 shows the percentage of patients adherent to CPAP 
at 1, 6, and 12 months, as defined by a mean nightly CPAP 
use ≥ 4 h/night. The percentage of patients adherent to CPAP 
progressively decreased over the 12-mo follow-up 
period. At 1 mo, 62% (n = 171) patients in the study 
were using CPAP ≥ 4 h/night, with a drop to 39% 
(n = 107) by 12 mo.
Predictors of Long-Term CPAP Adherence
On univariate analysis, the variables associated 
with CPAP adherence at 12 mo were sham and 1-mo 
CPAP adherence, baseline ESS score, change in ESS 
score from baseline to 1 mo, and loudness of snoring 
(Table 4). Increasing hours of daily use of CPAP during 
the sham trial and increasing CPAP adherence at 1 mo 
were significantly associated with higher CPAP adher-
ence at 12 mo. Lesser degrees of subjectively recorded 
sleepiness, as indicated by an ESS score between 0 to 
5, relative to a higher ESS score of 11 to 15, was associ-
ated with lower CPAP use at 12 mo. Greater reductions 
in ESS score from baseline to 1 mo were associated 
with higher levels of CPAP use at 12 mo. Patients who 
reported their snoring loudness as being “very loud” 
recorded increased hours of average daily CPAP use 
compared to those with quieter levels of snoring.
Age, sex, country of recruitment, and variables 
with P < 0.20 on univariate analysis, namely the type 
of medical department, baseline ESS score, change in 
ESS from baseline to 1 mo, sham CPAP adherence, 
1-mo CPAP adherence, CPAP side effect score, history 
of coronary artery disease only, history of TIA or stroke 
only, snoring loudness, snoring frequency, HADS 
anxiety score, and SF-36 bodily pain subscale score, 
were included in the multivariate analysis. The results 
of the multivariate analysis are shown in Table 5. Inde-
pendent predictors of CPAP adherence at 12 mo were 
the mean daily CPAP use at 1 mo (P < 0.0001) and the 
side effect score at 1 mo (P = 0.0038). The results equate 
to a 38-min increase in 12-mo CPAP use for every hour 
increase in CPAP use at 1 mo, and a 17-min reduction 
in 12-mo CPAP use for every one-point increase in the 
CPAP side effect score at 1 mo.
The frequency of CPAP side effects by category reported by 
patients at 1 mo are shown in Table 6. The most commonly 
reported CPAP side effects at 1 mo were dry mouth, nasal 
symptoms, and mask fit or leak problems. A significantly higher 
proportion of patients from Australia/New Zealand reported 
experiencing CPAP side effects compared to patients from 
China for six of the seven possible categories.
DISCUSSION
In patients with CVD and moderate to severe OSA in the 
treatment arm of the SAVE study, mean CPAP usage at the 
12-mo review was 3.3 ± 2.4 h/night. The factors that were 
found to predict successful, long-term CPAP adherence were 
the average hours of nightly CPAP use and side effects at 1 mo 
following initiation of therapy. Twelve-mo CPAP adherence 
was not found to be associated with nationality, SES, type 
of CVD, OSA severity (as measured by baseline OSA symp-
toms, ≥ 4% ODI or ESS score), or SF-36 or HADS scores.
Our finding that early CPAP use predicts long-term adher-
ence is consistent with results from previous studies. McArdle 
Figure 1—Flow diagram of patient recruitment and randomization.
Randomized into SAVE study 




arm (n = 296)
Patients analysed
n = 275
Underwent 1 week sham 
CPAP (n = 710)
Used sham CPAP ≥ 3 h/night 
(n = 603)
Excluded (n = 107)
• Used sham CPAP < 3 h/night (n = 72)
• Cheynes Stokes Respirations (n = 1)
• Other reasons (n = 34)
Excluded (n = 13)
• Ineligible for SAVE study (n = 10)
• Not randomized, reason unknown (n = 3)
Patients excluded from analysis (n = 21)
• Patient died (n = 1)
• Found to be ineligible (n = 2)
• Protocol violation (n = 5)
• Failed data download (n = 1)
• Did not attend 12m follow-up (n = 12)
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Age, y 60.4 ± 8.3 63.3 ± 8.1 60.9 ± 8.3
Males, n (%) 179 (80%) 42 (84%) 221 (80%)
BMI, kg/m2 27.6 ± 3.7 31.9 ± 4.3 28.3 (4.1)
Cardiovascular 
disease type, n (%)
CAD only 94 (42%) 46 (92%) 140 (51%)
TIA/stroke only 119 (53%) 3 (6%) 122 (44%)
TIA/stroke and CAD 12 (5%) 1 (2%) 13 (5%)
ESS score 7.5 ± 3.6 8.7 ± 3.3 7.7 ± 3.6
0 to 5, n (%) 78 (35%) 9 (18%) 87 (32%)
6 to 10 96 (43%) 23 (46%) 119 (43%)
10 to 15 51 (23%) 18 (36%) 69 (25%)
ODI, events/h 29.8 ± 14.3 24.3 ± 11.7 28.8 ± 14.0
12 to 20, n (%) 74 (33%) 27 (54%) 101 (37%)
> 20 to 30 55 (24%) 9 (18%) 64 (23%)
> 30 96 (43%) 14 (28%) 110 (40%)
Values are mean ± standard deviation or n (%). BMI, body mass index; 
CAD, coronary artery disease; ESS, Epworth Sleepiness Scale; ODI, 
oxygen desaturation index; TIA, transient ischemic attack.
Table 2—Continuous positive airway pressure adherence data – average 











Sham trial 5.1 ± 1.3 5.2 ± 1.4 5.1 ± 1.3
1 mo 4.3 ± 2.0 4.7 ± 2.2 4.4 ± 2.0
6 mo 3.7 ± 2.2 4.1 ± 2.7 3.8 ± 2.3
12 mo 3.2 ± 2.3 3.6 ± 2.9 3.3 ± 2.4
Values are mean ± SD.
Table 3—Continuous positive airway pressure adherence data – 











1 mo 137 (61%) 34 (68%) 171 (62%)
6 mo 117 (52%) 28 (56%) 145 (53%)
12 mo 84 (37%) 23 (46%) 107 (39%)
Estimate SE P value
Age, y -0.0013 0.017 0.94
Sex
Male -0.69 0.36 0.067
Female ref
BMI, kg/m2 -0.0073 0.036 0.84
Country
Australia and New Zealand 0.50 0.43 0.25
China ref
GDP adjusted 2.14 × 10-6 8.74 × 10-6 0.81
Type of medical department
Cardiology or general 0.11 0.48 0.82




No -0.47 0.30 0.12
Yes ref
TIA/stroke only
No 0.50 0.30 0.11
Yes ref
CAD and TIA/stroke
No -0.21 0.69 0.77
Yes ref
4% ODI, events/h 0.00072 0.010 0.49
Estimate SE P value
ESS at baseline
0 to 5 -0.85 0.34 0.016
6 to 10 -0.27 0.36 0.45
11 to 15 ref
Change in ESS from baseline 
to 1 mo, per unit decrease
0.14 0.05 0.003
Snoring loudness – very loud
No -0.76 0.30 0.016
Yes ref
Snoring frequency – almost every day
No -0.68 0.43 0.14
Yes ref
Breathing pauses – never or almost never
No 0.53 0.45 0.26
Yes ref
Early CPAP adherence
Sham trial, h/night 0.44 0.10 < 0.0001
1 mo, h/night 0.70 0.059 < 0.0001
CPAP side effects at 1 mo -0.18 0.11 0.097
HADS anxiety at baseline
< 8 -0.49 0.29 0.10
≥ 8 ref
HADS depression at baseline
< 8 -0.16 0.40 0.69
≥ 8 ref
SF-36 bodily pain subscale 0.011 0.0071 0.13
Table 4—Predictors of continuous positive airway pressure adherence at 12 mo – univariate analysis
BMI, body mass index; CAD, coronary artery disease; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Scale; GDP, gross domestic 
product; HADS, Hospital Anxiety and Depression Scale; 4% ODI, 4% oxygen desaturation index; SE, standard error; SF-36, Short Form-36 Health Survey; 
TIA, transient ischemic attack. Bold type indicates P < 0.05.
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et al. examined the determinants of objective CPAP compli-
ance in 1,211 consecutive patients with symptomatic OSA who 
were prescribed CPAP with a median duration of follow-up of 
22 mo (interquartile range, 12 to 36 mo).17 In this study, average 
nightly CPAP use at the first clinic visit (conducted within the 
first 3 mo of treatment initiation) ≥ 2 h/night was found to be 
strongly predictive of long term CPAP use. Similarly, in a study 
by Popescu et al.,27 increasing mean hours of CPAP use during an 
initial 2-w trial was associated with continuing CPAP use at 1 y.
Studies have shown that patterns of CPAP adherence are 
in fact established very early, possibly within the first week, 
following treatment initiation. Weaver et al. demonstrated in an 
analysis of the night-to-night variability between 17 “consis-
tent” (CPAP use > 90% of nights) and 15 “intermittent” users 
of CPAP that significant differences in the duration of use was 
evident between groups by the fourth night of therapy.14 This 
finding was confirmed in a subsequent study by Budhiraja et 
al.15 involving 100 patients with OSA treated with CPAP, which 
showed that good adherence to therapy (as defined by ≥ 4 h of 
CPAP use/night) at 3 days posttreatment initiation was predic-
tive of CPAP adherence measured at 30 days.
Side effects from CPAP are commonly reported, with approx-
imately two-thirds of patients reporting at least some degree of 
difficulty tolerating therapy.24 In our study, increasing side effect 
score at 1 mo was found to be independently associated with 
reduced CPAP adherence at 12 mo. Lewis et al. demonstrated that 
patients who reported problems during the first night of CPAP 
use had significantly lower CPAP usage after 1-mo follow-up.28 
Engleman et al. also found an increase in CPAP mask time (i.e., 
time spent at an effective CPAP pressure) at 1-3 mo in patients 
reporting no side effects from CPAP compared to those reporting 
at least one side effect (mean 4.1 ± standard error 0.6 versus 
2.4 ± 0.4 h/night, P = 0.02).29 However, an association between 
CPAP side effects and treatment adherence has not been consis-
tently demonstrated in other studies.20-22
Although CPAP adherence in the SAVE study appeared 
to be lower than ideal, with only 39% of patients using their 
device ≥ 4 h/night at 12 mo, our results are consistent with 
previous studies that have assessed CPAP use in patients with 
CVD. Others who have used CPAP in patients with OSA 
recruited from stroke services30-33 or patients with central sleep 
apnea recruited from heart failure clinics34 have shown similar 
patterns of adherence. For example, Martinez-Garcia et al. 
conducted a 5-y follow-up study involving 166 patients who 
underwent polysomnography testing at least 2 mo after suffering 
from an ischemic stroke.30 Of the 96 patients who were found 
to have moderate to severe OSA (i.e., AHI ≥ 20/h) and offered 
CPAP therapy, 43 patients (45%) withdrew therapy within the 
first 6 mo, and by 5 y follow-up, only 28 patients (29%) were 
using their device for ≥ 4 h/night on ≥ 70% of nights.
Table 5—Predictors of continuous positive airway pressure adherence at 
12 mo – multivariate analysis
Estimate SE P value
Age, y 0.014 0.016 0.36
Sex
Male -0.55 0.33 0.11
Female ref
Country
Australia and New Zealand 0.51 0.41 0.22
China ref
Type of medical department
Cardiology or general -0.14 0.36 0.71




No 0.69 0.59 0.25
Yes ref
TIA/stroke only
No 0.46 0.58 0.44
Yes ref
ESS at baseline
0 to 5 -0.05 0.42 0.9
6 to 10 0.46 0.33 0.17
11 to 15 ref
Change in ESS from baseline to 
1 mo, per unit decrease
0.041 0.048 0.40
Snoring loudness – very loud
No -0.28 0.26 0.30
Yes ref
Snoring frequency – almost every day
No -0.072 0.42 0.87
Yes ref
Early CPAP adherence
Sham trial, h/night 0.04 0.10 0.71
1 mo, h/night 0.64 0.075 < 0.0001
CPAP side effects at 1 mo -0.29 0.097 0.0038
HADS anxiety at baseline
< 8 -0.19 0.27 0.48
≥ 8 ref
SF-36 bodily pain subscale 0.0078 0.0068 0.25
CAD, coronary artery disease; CPAP, continuous positive airway 
pressure; ESS, Epworth Sleepiness Scale; GDP, gross domestic product; 
HADS, Hospital Anxiety and Depression Scale; 4% ODI, 4% oxygen 
desaturation index; SE, standard error; SF-36, Short Form-36 Health 
Survey; TIA, transient ischemic attack. Bold type indicates P < 0.05.
Table 6—Frequency of reported continuous positive airway pressure side 












1. Dry mouth 86 (38%) 29 (58%)a 115 (42%)
2. Nasal symptoms 60 (27%) 24 (48%)a 84 (31%)
3. Eye problems 13 (6%) 12 (24%)a 25 (9%)
4. Claustrophobia 1 (0.4%) 2 (4%)a 3 (1%)
5. Noise problems 22 (10%) 5 (10%) 27 (10%)
6. Soreness or skin irritation 29 (13%) 18 (36%)a 47 (17%)
7. Mask fit or leak problems 42 (19%) 21 (42%)a 63 (23%)
aP < 0.05 for the difference between China and Australia/New Zealand.
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A recently published Spanish study by Barbé et al.35 exam-
ined the effect of CPAP therapy on the incidence of CV events 
in nonsleepy (i.e., ESS ≤ 10) patients with OSA. They showed 
no effect of CPAP therapy on the incidence of hypertension and 
CV events among patients overall, but on post hoc analysis a 
statistically significant reduction in the incidence of hyperten-
sion and CV events was found amongst those patients using 
CPAP ≥ 4 h/night. Barbé et al. reported a higher CPAP adher-
ence rate than in our study, with 230 of 357 patients (64%) in 
the treatment arm using CPAP for ≥ 4 h/night after a median 
4-y follow-up. The reason for the difference in CPAP adherence 
is unclear, although patients in their study were recruited from 
sleep clinics with symptoms of snoring and witnessed apneas 
with no prior history of a CV event. In contrast, participants 
in the current study were recruited in stroke or cardiac clinics, 
were on average 10 y older, with established CVD at entry, and 
most had little to no prior knowledge or concern about OSA. 
Thus, the differences in CPAP adherence between the two 
studies may relate to differences in patient selection, average 
age, and degree of underlying CV morbidity.
No previous studies have directly compared long-term 
CPAP adherence in Chinese and Caucasian populations. A 
recently published study by Wang et al. assessed CPAP adher-
ence in a group of 193 patients with OSA in China36 and also 
found relatively low compliance levels. After a mean (± SD) 
follow-up period of 59 (± 32) mo, only 100 patients (52%) 
patients reported still using CPAP, of whom 17 patients did not 
fulfill adherence criteria (as defined by CPAP use ≥ 4 h/night 
for ≥ 70% of nights per w). Sixty-four patients (33%) reported 
that therapy did not commence after the initial CPAP titration 
study, and 29 patients (15%) discontinued CPAP after an initial 
period of use. Another study by Hui et al.21 previously evaluated 
the pattern and determinants of CPAP compliance in a Chinese 
population residing in Hong Kong. In a group of 112 newly 
diagnosed patients with OSA (AHI ≥ 10 events/h) plus self-
reported sleepiness in a respiratory clinic, objective compliance 
was 5.4 ± 1.6 h/night at 1 mo and 5.3 ± 1.6 h/night at 3 mo. The 
percentage of patients using CPAP ≥ 4 h/night for at least 70% 
of nights was 75 ± 28% at 1 mo and 72 ± 28% at 3 mo, which 
is higher than in the SAVE study. Unlike our study findings, the 
only factor found to be predictive of CPAP compliance at 1 and 
3 mo was a high baseline AHI, and CPAP side effects were not 
found to be associated with treatment adherence. Other studies 
have also found disease severity, as measured by either the 
AHI or ODI, to be an independent predictor of CPAP adher-
ence17-19,27; however, this was not demonstrated in our study 
population, nor in several other studies.15,29
It is noteworthy that country or region was not a significant 
predictor of CPAP adherence. CPAP treatment for OSA was 
discovered in Australia approximately 30 y ago37 and is now 
widely deployed as first-line treatment for OSA. All but one of 
the sites in Australia and New Zealand involved in the SAVE 
study at this time were led by respiratory investigators expe-
rienced with CPAP treatment. By comparison, sleep services 
in China and CPAP availability in particular were markedly 
limited. Furthermore, one-third (12 of 37) of the sites in China 
were led by neurologists or cardiologists with no previous expe-
rience in the diagnosis or management of OSA. Thus, it appears 
that the SAVE study protocols, investigator training, and patient 
educational materials ensured a reasonably even level of CPAP 
adherence despite diverse cultural and medical experiences.
The finding in the current study that adherence and side 
effects at 1 mo were independent predictors of long-term CPAP 
use has direct implications for the conduct of the SAVE study. 
Although the finding of a CPAP adherence level of 3.3 h/night 
at 12 mo is in keeping with our a priori assumption about long-
term CPAP adherence levels in this study population, early, 
more intensive in-trial interventions to optimize CPAP use and 
minimize side effects may nevertheless improve long-term 
CPAP compliance and the chances of showing a benefit with 
respect to CV outcomes. The findings also point to the general 
challenge of deploying CPAP treatment for OSA in minimally 
symptomatic, nonsleep center-referred patients who have 
significant co-morbidities.
It was interesting to note that the baseline characteris-
tics of patients with OSA and CVD were different between 
those recruited from China and those from Australia and New 
Zealand, with Chinese patients having an overall lower mean 
BMI and ESS scores but greater severity of OSA as determined 
by the ≥ 4% ODI. Previous studies have reported a similar 
prevalence of OSA in Asian countries compared to Caucasian 
populations despite a lower prevalence of obesity.38,39 Craniofa-
cial abnormalities that cause structural narrowing of the upper 
airway are thought to be an important risk factor for OSA in 
Asian populations.40 It was also interesting to find a higher 
proportion of patients reporting CPAP side effects at 1 mo from 
the Australia/New Zealand group compared to those from China. 
Although it is possible that some of these differences may have 
resulted from anatomical/physiological variations between the 
groups, the fact that significant differences between them were 
noted in all but one side effect category suggests that cultural 
differences and/or reporting biases were the likely reasons.
Our study has several limitations. Most of the participants in 
this study were from China, with a smaller number of patients 
from Australia and New Zealand. It may be difficult to gener-
alize the findings to other cultural or ethnic groups, although the 
convergence of results between these two remarkably different 
cultural, ethnic, and medical systems suggests to us that this is 
not a major limitation of our study. We also acknowledge that the 
patients in this study had already been given a 1-w trial of sham 
CPAP prior to study entry and were excluded if they did not use 
CPAP for at least 3 h during the sham trial. Therefore, patients 
who did not initially tolerate or accept CPAP therapy were not 
included in our analysis. However, 85% of patients who under-
took the sham CPAP trial used the device for at least 3 h and were 
potentially eligible for inclusion in the SAVE study. Although 
exclusion of the 15% of patients in whom the sham trial failed 
may have resulted in a slight elevation in the adherence rates, we 
believe this is a reflection of clinical practice whereby patients 
will trial CPAP prior to committing to long-term therapy.
In summary, this is a report of our early experience with 
CPAP use in patients at high CVD risk with moderate to severe 
OSA in the treatment arm of the SAVE study, who have been 
recruited from China, Australia, and New Zealand. CPAP 
adherence in the study group overall at 12 mo was similar to 
previous studies of adherence, and although it appeared to be 
relatively low with less than 40% of participants using their 
CPAP device for at least 4 h per night after 12 mo, this was 
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not unexpected given the selection of patients from cardiovas-
cular clinics, with an average age greater than that generally 
encountered in sleep clinic populations and with high levels of 
cardiovascular comorbidity. Average nightly CPAP use and the 
number of side effects at 1 mo were found to be independent 
predictors of long-term CPAP adherence. Thus, interventions 
to optimize early CPAP use and minimize side effects may be 
helpful in improving longer term CPAP adherence in patients 
with CVD and moderate to severe OSA.
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SUPPLEMENTAL MATERIAL
Figure S1—CPAP Troubleshooting Guide for SAVE Investigators/Study Coordinators.
